Tvardi Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	21.42	31.61	22.92	21.49
Short-Term Investments	15.04	-	-	22.25
Cash & Short-Term Investments	36.46	31.61	22.92	43.74
Cash Growth	286.31%	37.94%	-47.60%	-
Prepaid Expenses	1.98	0.07	3.24	0.37
Total Current Assets	38.44	31.69	26.16	44.11
Property, Plant & Equipment	0.22	0.3	0.38	0.46
Other Intangible Assets	0.34	0.39	0.45	0.51
Long-Term Deferred Charges	-	2.81	-	-
Other Long-Term Assets	0.02	0.02	0.02	0.02
Total Assets	39.02	35.2	27	45.1
Accounts Payable	4.08	2.19	1.61	2.41
Accrued Expenses	6.85	8.08	1.58	1.79
Current Portion of Leases	0.11	0.1	0.09	0.08
Total Current Liabilities	11.04	10.37	3.28	4.28
Long-Term Debt	-	30.26	-	-
Long-Term Leases	0.12	0.2	0.28	0.37
Total Liabilities	11.16	40.83	3.56	4.65
Common Stock	0.01	0.02	0.02	0.02
Additional Paid-In Capital	131.03	1.09	0.76	0.45
Retained Earnings	-103.18	-92.24	-62.84	-45.49
Comprehensive Income & Other	0.01	-	-	-0.02
Total Common Equity	27.87	-91.13	-62.06	-45.05
Shareholders' Equity	27.87	-5.63	23.45	40.45
Total Liabilities & Equity	39.02	35.2	27	45.1
Total Debt	0.23	30.56	0.37	0.45
Net Cash (Debt)	36.23	1.05	22.55	43.29
Net Cash Growth	296.45%	-95.34%	-47.91%	-
Net Cash Per Share	3.80	0.16	3.54	6.79
Filing Date Shares Outstanding	9.38	6.4	6.38	6.37
Total Common Shares Outstanding	9.38	6.4	6.38	6.37
Working Capital	27.4	21.32	22.88	39.83
Book Value Per Share	2.97	-14.24	-9.73	-7.07
Tangible Book Value	27.53	-91.52	-62.51	-45.56
Tangible Book Value Per Share	2.93	-14.30	-9.80	-7.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q